Compare
Lunai Bioworks Inc. vs HCW Biologics Inc. vs Connect Biopharma Holdings Ltd vs Inovio Pharmaceuticals, Inc.
| Latest fiscal year | Lunai Bioworks Inc. LNAI | HCW Biologics Inc. HCWB | Connect Biopharma Holdings Ltd CNTB | Inovio Pharmaceuticals, Inc. INO |
|---|---|---|---|---|
| Year ended | 2026-06-30 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $52.0K | $54.2K | $64.0K | $65.3K |
| Revenue growth (YoY) | n/a | -97.9% | -99.8% | -70.0% |
| Gross margin | n/a | 20.0% | n/a | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$3.56M | -$7.96M | -$55.48M | -$84.95M |
| EPS (Diluted) | -$1.06 | -$10.63 | -$1.00 | -$1.81 |
| Operating cash flow | -$5.29M | -$13.39M | -$51.21M | -$88.63M |
| Free cash flow | -$5.29M | -$13.39M | -$51.64M | -$88.92M |
| Cash & equivalents | $1.71M | $1.95M | $38.34M | $44.27M |
| Total assets | $9.94M | $24.52M | $56.08M | $74.31M |
| Total liabilities | $18.97M | $21.76M | $14.10M | $50.21M |
| Shareholders' equity | -$9.02M | $2.76M | $41.98M | $24.10M |
| Return on year-end equity | n/a | -287.9% | -132.2% | -352.5% |
| Shares outstanding | 4.62M | n/a | 56.44M | 69.00M |
Revenue, most recent five fiscal years
| Fiscal year | Lunai Bioworks Inc. | HCW Biologics Inc. | Connect Biopharma Holdings Ltd | Inovio Pharmaceuticals, Inc. |
|---|---|---|---|---|
| Latest | $52.0K Ended 2026-06-30 | $54.2K Ended 2025-12-31 | $64.0K Ended 2025-12-31 | $65.3K Ended 2025-12-31 |
| 1 year earlier | n/a | $2.57M Ended 2024-12-31 | $26.03M Ended 2024-12-31 | $217.8K Ended 2024-12-31 |
| 2 years earlier | n/a | $2.84M Ended 2023-12-31 | $0 Ended 2023-12-31 | $832.0K Ended 2023-12-31 |
| 3 years earlier | n/a | $6.72M Ended 2022-12-31 | n/a | $10.26M Ended 2022-12-31 |
| 4 years earlier | n/a | $0 Ended 2021-12-31 | n/a | $1.77M Ended 2021-12-31 |